Boston Scientific EPS Miss, Stock Down 2%

Boston Scientific reported Q1 adjusted EPS of $0.80, beating consensus $0.79, with revenue $5.20 bn, up 11.6% YoY.
The company forecast full‑year adjusted EPS of $3.34‑$3.41, midpoint $3.38, below analyst consensus of $3.45, prompting a 2.2% share decline.
Cardiovascular segment revenue hit $3.50 bn (+13.5% reported, +11.2% organic) while MedSurg generated $1.70 bn (+7.8% reported, +5.7% organic).
Boston Scientific expects Q2 revenue growth 5.5‑7.5% and adjusted EPS $0.82‑$0.84, and announced positive trial results for WATCHMAN FLX and EKOS devices.